Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21
March 17 2017 - 7:03AM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused
on the development of nervous system therapies based on its neural
stem cell technology, announces that Rich Daly, Chairman and CEO of
Neuralstem, will present at the Oppenheimer 27th Annual
Healthcare Conference at The Westin New York Grand Central in New
York. The presentation is scheduled for Tuesday, March 21,
2017 at 1:00 p.m. Eastern time.
The live audio webcast of the presentation can be
accessed here: Neuralstem. An archive of the
presentation will be available approximately three hours after the
live event and will be available for 90 days.
About Neuralstem Neuralstem’s
patented technology enables the commercial-scale production of
multiple types of central nervous system stem cells, which are
being developed as potential therapies for multiple central nervous
system diseases and conditions.
Neuralstem’s technology enables the discovery of
small molecule compounds by systematic screening chemical compounds
against its proprietary human hippocampal stem cell line. The
screening process has led to the discovery and patenting of
molecules that Neuralstem believes may stimulate the brain’s
capacity to generate new neurons, potentially reversing
pathophysiologies associated with certain central nervous system
(CNS) conditions.
The company has completed Phase 1a and 1b trials
evaluating NSI-189, a novel neurogenic small molecule product
candidate, for the treatment of major depressive disorder or MDD,
and is currently conducting a Phase 2 efficacy study for MDD.
Neuralstem’s stem cell therapy product candidate,
NSI-566, is a spinal cord-derived neural stem cell line. Neuralstem
is currently evaluating NSI-566 in three indications: stroke,
chronic spinal cord injury (cSCI), and Amyotrophic Lateral
Sclerosis (ALS).
Neuralstem is conducting a Phase 1 safety study for
the treatment of paralysis from chronic motor stroke at the BaYi
Brain Hospital in Beijing, China. In addition, NSI-566 was
evaluated in a Phase 1 safety study to treat paralysis due to
chronic spinal cord injury as well as a Phase 1 and Phase 2a risk
escalation, safety trials for ALS. Subjects from all three
indications are currently in long-term observational follow-up
periods to continue to monitor safety and possible therapeutic
benefits.
Cautionary Statement Regarding Forward
Looking InformationThis news release contains
“forward-looking statements” made pursuant to the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements relate to future, not past, events
and may often be identified by words such as “expect,”
“anticipate,” “intend,” “plan,” “believe,” “seek” or “will.”
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Specific risks and
uncertainties that could cause our actual results to differ
materially from those expressed in our forward-looking statements
include risks inherent in the development and commercialization of
potential products, uncertainty of clinical trial results or
regulatory approvals or clearances, need for future capital,
dependence upon collaborators and maintenance of our intellectual
property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements. Additional
information on potential factors that could affect our results and
other risks and uncertainties are detailed from time to time in
Neuralstem’s periodic reports, including the Annual Report on Form
10-K for the year ended December 31, 2015, and Form 10-Q for the
nine months ended September 30, 2016, filed with the Securities and
Exchange Commission (SEC), and in other reports filed with the SEC.
We do not assume any obligation to update any forward-looking
statements.
Contact:
Danielle Spangler
Investor Relations
Neuralstem, Inc
301.366.1481
Lori Rosen
Public Relations
LDR Communications
917.553.6808
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2023 to Apr 2024